Psychedelics are a hallucinogenic class of psychoactive drugs with the primary effect of activating non-ordinary states of consciousness. Due to the positive preliminary findings of these drugs in the treatment of psychiatric disorders, the number of registered clinical studies has risen significantly. In this paper, clinical studies registered on clinicaltr...
Back to table of contents Previous article Next article ViewpointsFull AccessThe Return of Psychedelics: Still Time to Prevent TragedyStanley N. Caroff, M.D.Stanley N. Caroff, M.D.Published Online:31 Mar 2021https://doi.org/10.1176/appi.pn.2021.4.8AbstractRecently, a movement reviving psychedelic drugs has emerged among physicians, echoed by activists like M...
BackgroundPsilocybin is the psychoactive component in Psilocybe mushrooms ('magic mushrooms'). Whether and how the quality of the psilocybin-induced experience might mediate beneficial health outcomes is currently under investigation, for example, in therapeutic applications. However, to date, no meta-analysis has investigated the dose-dependency of subjecti...
Serotonergic psychedelic drugs, such as psilocin (4-hydroxy-N,N-dimethyltryptamine), profoundly alter the quality of consciousness through mechanisms which are incompletely understood. Growing evidence suggests that a single psychedelic experience can positively impact long-term psychological well-being, with relevance for the treatment of psychiatric disord...
Psilocybin is a classic serotonergic hallucinogen acting on the 5-HT2A receptor. It is used recreationally and in psychiatric research. Selective serotonin reuptake inhibitors (SSRIs) like escitalopram are first-line treatments for depression. They inhibit the serotonin transporter (SERT). This might cause a possible downregulation of postsynaptic 5-HT recep...
In this interview, we discuss the use of psychedelic drugs as a promising treatment in disorders of consciousness. Psilocybin, a classic psychedelic, is currently undergoing substantial clinical investigations in healthy volunteers, but also in clinical populations. Recently, experts in the field of psychedelics have addressed the attractive possibility to u...
Back to table of contents Previous article Next article Journal DigestFull AccessJournal Digest: Home Environment; Postpartum Mental Illness; Placebo in Psychedelic Study; Single Gene Mutation; TopiramateNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:28 May 2020https://doi.org/10.1176/appi.pn.2020.6a34Nurturing Home Environme...
Back to table of contents Previous article Next article Clinical & ResearchFull AccessCan Psychedelics Radically Change SUD Treatment?Katie O'ConnorKatie O'ConnorPublished Online:20 Mar 2020https://doi.org/10.1176/appi.pn.2020.2a12AbstractThough the field is young, psychedelics appear to hold promise as a treatment for addiction, even as barriers to research...
Psychiatry is in a crisis. Mental health disorders are on the rise worldwide and there are currently not enough efficient treatment methods that would meet the patients’ needs. Hence, the societal and economic costs of mental health problems are enormous, as well as the suffering of individuals afflicted by mental health problems. Lysergic acid diethylamide ...
Machine Learning is used to predict the efficacy of psilocybin in treating mental health and addiction by using a random forest algorithm. Psilocybin is a chemical compound found in fungi. Following ingestion, it is converted to psilocin which acts as a serotonin agonist, producing altered states of consciousness and hallucinations. Research suggests the use...
ObjectiveThe relationship between ketamine's hallucinogenic- and dissociative-type effects and antidepressant mechanism of action is poorly understood. This paper reviewed the correlation between subjective effects defined by various psychometric scales and observed clinical outcomes in the treatment of patients with Major Depressive Disorder (MDD).MethodsBa...
Back to table of contents Previous article Next article ProfessionalFull AccessJohns Hopkins Opens Research Center on PsychedelicsNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:28 Oct 2019https://doi.org/10.1176/appi.pn.2019.10a16AbstractA total of $17 million in private donations to the Hopkins center is expected to provide ...
Psychedelics are powerful psychoactive substances that alter consciousness and brain function. Like cannabis, psychedelics have long been considered prohibited Schedule I substances under the Controlled Substances Act of 1970. However, via the powerful psychological experiences they induce, psychedelics are now being shown to be viable therapeutic alternativ...
psilocybin; depression; terminal cancer; CME; CNE: psilocybin; depression; terminal cancer; CME; CNEPsilocybin is a naturally occurring alkaloid found in more than 200 species of mushrooms. This compound, which was first isolated by the Swiss chemist Albert Hofman in 1959, is the active constituent of psychedelic mushrooms which are thought to have been util...
Psychedelic substances have regained interest as therapeutic agents in the treatment of stress-related disorders. The effects seem to be of persisting nature even after a single dose. Also in lower than 'regular' recreational doses, so-called micro-doses, without the typical effects on consciousness, users report beneficial effects on cognitive processes and...
Back to table of contents Previous article Next article Clinical and Research NewsFull AccessIs Psychedelic Medicine on the Horizon?Nick ZagorskiNick ZagorskiPublished Online:28 Feb 2019https://doi.org/10.1176/appi.pn.2019.1b1AbstractNew research suggests that, if used properly, psychedelic compounds may be able to help patients with treatment-resistant psyc...
Based on its ability to increase brain complexity, a seemingly reliable index of conscious level, we propose testing the capacity of the classic psychedelic, psilocybin, to increase conscious awareness in patients with disorders of consciousness. We also confront the considerable ethical and practical challenges this proposal must address, if this hypothesis...
This article provides an ethical analysis of psychedelic research involving disorders of consciousness patients. We apply two internationally accepted approaches for analyzing the ethics of human research, the Value-Validity Framework and Component Analysis, to a research program recently proposed by Scott and Carhart-Harris. We focus on Scott and Carhart-Ha...
The purpose of this paper is to provide an integrative review and offer novel insights regarding human research with classic psychedelics (classic hallucinogens), which are serotonin 2A receptor (5-HT2AR) agonists such as lysergic acid diethylamide (LSD), mescaline, and psilocybin. Classic psychedelics have been administered as sacraments since ancient times...
It has often been suggested in the popular and academic literature that the psychedelic state qualifies as a higher state of consciousness relative to the state of normal waking awareness. This article subjects this proposal to critical scrutiny, focusing on the question of what it would mean for a state of consciousness to be 'higher'. We begin by consideri...
